Biological biomarkers of oral cancer
The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per year from 2005 to 2017, with higher survival rates when detected at early stages. Based on histopathological grading of oral dysplasia, it is estimat...
Gespeichert in:
| Veröffentlicht in: | Periodontology 2000 2024-10, Vol.96 (1), p.250-280 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 280 |
|---|---|
| container_issue | 1 |
| container_start_page | 250 |
| container_title | Periodontology 2000 |
| container_volume | 96 |
| creator | Radaic, Allan Kamarajan, Pachiyappan Cho, Alex Wang, Sandy Hung, Guo‐Chin Najarzadegan, Fereshteh Wong, David T. Ton‐That, Hung Wang, Cun‐Yu Kapila, Yvonne L. |
| description | The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per year from 2005 to 2017, with higher survival rates when detected at early stages. Based on histopathological grading of oral dysplasia, it is estimated that severe dysplasia has a malignant transformation rate of 7%–50%. Despite these numbers, oral dysplasia grading does not reliably predict its clinical behavior. Thus, more accurate markers predicting oral dysplasia progression to cancer would enable better targeting of these lesions for closer follow‐up, especially in the early stages of the disease. In this context, molecular biomarkers derived from genetics, proteins, and metabolites play key roles in clinical oncology. These molecular signatures can help predict the likelihood of OSCC development and/or progression and have the potential to detect the disease at an early stage and, support treatment decision‐making and predict treatment responsiveness. Also, identifying reliable biomarkers for OSCC detection that can be obtained non‐invasively would enhance management of OSCC. This review will discuss biomarkers for OSCC that have emerged from different biological areas, including genomics, transcriptomics, proteomics, metabolomics, immunomics, and microbiomics. |
| doi_str_mv | 10.1111/prd.12542 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11163022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2902937910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4162-2161193247f6edf6b228990445888a2066370fb791404c3eb1a78feea8d4248d3</originalsourceid><addsrcrecordid>eNp1kMtKAzEUhoMotlYXvoB04UIXY08uk8tKtF6hoIiuQyaTqaPTpiat0rc3OrXowmwOyfn48vMjtI_hBKczmIXyBJOckQ3UxRwgA5GLTdQFBTzjAtMO2onxBQALRfNt1KESBAWMu-jwvPaNH9fWNP2i9hMTXl2IfV_1fUhP1kytC7toqzJNdHur2UNPV5ePw5tsdHd9OzwbZZZhTjKCOcaKEiYq7sqKF4RIpYCxXEppCHBOBVSFUJgBs9QV2AhZOWdkyQiTJe2h09Y7WxQTV1o3nacQehbqlGupvan13820ftZj_65TCZwCIclwtDIE_7Zwca4ndbSuaczU-UXURAFRNCWAhB63qA0-xuCq9T8YvoQ43Uv9XWtiD34HW5M_PSZg0AIfdeOW_5v0_cNFq_wE085_nQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2902937910</pqid></control><display><type>article</type><title>Biological biomarkers of oral cancer</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Radaic, Allan ; Kamarajan, Pachiyappan ; Cho, Alex ; Wang, Sandy ; Hung, Guo‐Chin ; Najarzadegan, Fereshteh ; Wong, David T. ; Ton‐That, Hung ; Wang, Cun‐Yu ; Kapila, Yvonne L.</creator><creatorcontrib>Radaic, Allan ; Kamarajan, Pachiyappan ; Cho, Alex ; Wang, Sandy ; Hung, Guo‐Chin ; Najarzadegan, Fereshteh ; Wong, David T. ; Ton‐That, Hung ; Wang, Cun‐Yu ; Kapila, Yvonne L.</creatorcontrib><description>The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per year from 2005 to 2017, with higher survival rates when detected at early stages. Based on histopathological grading of oral dysplasia, it is estimated that severe dysplasia has a malignant transformation rate of 7%–50%. Despite these numbers, oral dysplasia grading does not reliably predict its clinical behavior. Thus, more accurate markers predicting oral dysplasia progression to cancer would enable better targeting of these lesions for closer follow‐up, especially in the early stages of the disease. In this context, molecular biomarkers derived from genetics, proteins, and metabolites play key roles in clinical oncology. These molecular signatures can help predict the likelihood of OSCC development and/or progression and have the potential to detect the disease at an early stage and, support treatment decision‐making and predict treatment responsiveness. Also, identifying reliable biomarkers for OSCC detection that can be obtained non‐invasively would enhance management of OSCC. This review will discuss biomarkers for OSCC that have emerged from different biological areas, including genomics, transcriptomics, proteomics, metabolomics, immunomics, and microbiomics.</description><identifier>ISSN: 0906-6713</identifier><identifier>ISSN: 1600-0757</identifier><identifier>EISSN: 1600-0757</identifier><identifier>DOI: 10.1111/prd.12542</identifier><identifier>PMID: 38073011</identifier><language>eng</language><publisher>Denmark: John Wiley and Sons Inc</publisher><subject>biomarkers ; Biomarkers, Tumor ; Carcinoma, Squamous Cell - diagnosis ; Carcinoma, Squamous Cell - genetics ; Disease Progression ; Genomics ; human papilloma virus (HPV) ; Humans ; immunomics ; Metabolomics ; microbiomics ; Mouth Neoplasms - diagnosis ; OPMD ; oral potentially malignant disorders ; oral squamous cell carcinoma ; OSCC ; Proteomics ; Review</subject><ispartof>Periodontology 2000, 2024-10, Vol.96 (1), p.250-280</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2023 The Authors. Periodontology 2000 published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4162-2161193247f6edf6b228990445888a2066370fb791404c3eb1a78feea8d4248d3</citedby><cites>FETCH-LOGICAL-c4162-2161193247f6edf6b228990445888a2066370fb791404c3eb1a78feea8d4248d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fprd.12542$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fprd.12542$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38073011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Radaic, Allan</creatorcontrib><creatorcontrib>Kamarajan, Pachiyappan</creatorcontrib><creatorcontrib>Cho, Alex</creatorcontrib><creatorcontrib>Wang, Sandy</creatorcontrib><creatorcontrib>Hung, Guo‐Chin</creatorcontrib><creatorcontrib>Najarzadegan, Fereshteh</creatorcontrib><creatorcontrib>Wong, David T.</creatorcontrib><creatorcontrib>Ton‐That, Hung</creatorcontrib><creatorcontrib>Wang, Cun‐Yu</creatorcontrib><creatorcontrib>Kapila, Yvonne L.</creatorcontrib><title>Biological biomarkers of oral cancer</title><title>Periodontology 2000</title><addtitle>Periodontol 2000</addtitle><description>The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per year from 2005 to 2017, with higher survival rates when detected at early stages. Based on histopathological grading of oral dysplasia, it is estimated that severe dysplasia has a malignant transformation rate of 7%–50%. Despite these numbers, oral dysplasia grading does not reliably predict its clinical behavior. Thus, more accurate markers predicting oral dysplasia progression to cancer would enable better targeting of these lesions for closer follow‐up, especially in the early stages of the disease. In this context, molecular biomarkers derived from genetics, proteins, and metabolites play key roles in clinical oncology. These molecular signatures can help predict the likelihood of OSCC development and/or progression and have the potential to detect the disease at an early stage and, support treatment decision‐making and predict treatment responsiveness. Also, identifying reliable biomarkers for OSCC detection that can be obtained non‐invasively would enhance management of OSCC. This review will discuss biomarkers for OSCC that have emerged from different biological areas, including genomics, transcriptomics, proteomics, metabolomics, immunomics, and microbiomics.</description><subject>biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Squamous Cell - diagnosis</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Disease Progression</subject><subject>Genomics</subject><subject>human papilloma virus (HPV)</subject><subject>Humans</subject><subject>immunomics</subject><subject>Metabolomics</subject><subject>microbiomics</subject><subject>Mouth Neoplasms - diagnosis</subject><subject>OPMD</subject><subject>oral potentially malignant disorders</subject><subject>oral squamous cell carcinoma</subject><subject>OSCC</subject><subject>Proteomics</subject><subject>Review</subject><issn>0906-6713</issn><issn>1600-0757</issn><issn>1600-0757</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kMtKAzEUhoMotlYXvoB04UIXY08uk8tKtF6hoIiuQyaTqaPTpiat0rc3OrXowmwOyfn48vMjtI_hBKczmIXyBJOckQ3UxRwgA5GLTdQFBTzjAtMO2onxBQALRfNt1KESBAWMu-jwvPaNH9fWNP2i9hMTXl2IfV_1fUhP1kytC7toqzJNdHur2UNPV5ePw5tsdHd9OzwbZZZhTjKCOcaKEiYq7sqKF4RIpYCxXEppCHBOBVSFUJgBs9QV2AhZOWdkyQiTJe2h09Y7WxQTV1o3nacQehbqlGupvan13820ftZj_65TCZwCIclwtDIE_7Zwca4ndbSuaczU-UXURAFRNCWAhB63qA0-xuCq9T8YvoQ43Uv9XWtiD34HW5M_PSZg0AIfdeOW_5v0_cNFq_wE085_nQ</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Radaic, Allan</creator><creator>Kamarajan, Pachiyappan</creator><creator>Cho, Alex</creator><creator>Wang, Sandy</creator><creator>Hung, Guo‐Chin</creator><creator>Najarzadegan, Fereshteh</creator><creator>Wong, David T.</creator><creator>Ton‐That, Hung</creator><creator>Wang, Cun‐Yu</creator><creator>Kapila, Yvonne L.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202410</creationdate><title>Biological biomarkers of oral cancer</title><author>Radaic, Allan ; Kamarajan, Pachiyappan ; Cho, Alex ; Wang, Sandy ; Hung, Guo‐Chin ; Najarzadegan, Fereshteh ; Wong, David T. ; Ton‐That, Hung ; Wang, Cun‐Yu ; Kapila, Yvonne L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4162-2161193247f6edf6b228990445888a2066370fb791404c3eb1a78feea8d4248d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Squamous Cell - diagnosis</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Disease Progression</topic><topic>Genomics</topic><topic>human papilloma virus (HPV)</topic><topic>Humans</topic><topic>immunomics</topic><topic>Metabolomics</topic><topic>microbiomics</topic><topic>Mouth Neoplasms - diagnosis</topic><topic>OPMD</topic><topic>oral potentially malignant disorders</topic><topic>oral squamous cell carcinoma</topic><topic>OSCC</topic><topic>Proteomics</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Radaic, Allan</creatorcontrib><creatorcontrib>Kamarajan, Pachiyappan</creatorcontrib><creatorcontrib>Cho, Alex</creatorcontrib><creatorcontrib>Wang, Sandy</creatorcontrib><creatorcontrib>Hung, Guo‐Chin</creatorcontrib><creatorcontrib>Najarzadegan, Fereshteh</creatorcontrib><creatorcontrib>Wong, David T.</creatorcontrib><creatorcontrib>Ton‐That, Hung</creatorcontrib><creatorcontrib>Wang, Cun‐Yu</creatorcontrib><creatorcontrib>Kapila, Yvonne L.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Periodontology 2000</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Radaic, Allan</au><au>Kamarajan, Pachiyappan</au><au>Cho, Alex</au><au>Wang, Sandy</au><au>Hung, Guo‐Chin</au><au>Najarzadegan, Fereshteh</au><au>Wong, David T.</au><au>Ton‐That, Hung</au><au>Wang, Cun‐Yu</au><au>Kapila, Yvonne L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological biomarkers of oral cancer</atitle><jtitle>Periodontology 2000</jtitle><addtitle>Periodontol 2000</addtitle><date>2024-10</date><risdate>2024</risdate><volume>96</volume><issue>1</issue><spage>250</spage><epage>280</epage><pages>250-280</pages><issn>0906-6713</issn><issn>1600-0757</issn><eissn>1600-0757</eissn><abstract>The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per year from 2005 to 2017, with higher survival rates when detected at early stages. Based on histopathological grading of oral dysplasia, it is estimated that severe dysplasia has a malignant transformation rate of 7%–50%. Despite these numbers, oral dysplasia grading does not reliably predict its clinical behavior. Thus, more accurate markers predicting oral dysplasia progression to cancer would enable better targeting of these lesions for closer follow‐up, especially in the early stages of the disease. In this context, molecular biomarkers derived from genetics, proteins, and metabolites play key roles in clinical oncology. These molecular signatures can help predict the likelihood of OSCC development and/or progression and have the potential to detect the disease at an early stage and, support treatment decision‐making and predict treatment responsiveness. Also, identifying reliable biomarkers for OSCC detection that can be obtained non‐invasively would enhance management of OSCC. This review will discuss biomarkers for OSCC that have emerged from different biological areas, including genomics, transcriptomics, proteomics, metabolomics, immunomics, and microbiomics.</abstract><cop>Denmark</cop><pub>John Wiley and Sons Inc</pub><pmid>38073011</pmid><doi>10.1111/prd.12542</doi><tpages>31</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0906-6713 |
| ispartof | Periodontology 2000, 2024-10, Vol.96 (1), p.250-280 |
| issn | 0906-6713 1600-0757 1600-0757 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11163022 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | biomarkers Biomarkers, Tumor Carcinoma, Squamous Cell - diagnosis Carcinoma, Squamous Cell - genetics Disease Progression Genomics human papilloma virus (HPV) Humans immunomics Metabolomics microbiomics Mouth Neoplasms - diagnosis OPMD oral potentially malignant disorders oral squamous cell carcinoma OSCC Proteomics Review |
| title | Biological biomarkers of oral cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A32%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20biomarkers%20of%20oral%20cancer&rft.jtitle=Periodontology%202000&rft.au=Radaic,%20Allan&rft.date=2024-10&rft.volume=96&rft.issue=1&rft.spage=250&rft.epage=280&rft.pages=250-280&rft.issn=0906-6713&rft.eissn=1600-0757&rft_id=info:doi/10.1111/prd.12542&rft_dat=%3Cproquest_pubme%3E2902937910%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2902937910&rft_id=info:pmid/38073011&rfr_iscdi=true |